33 results about "Lipid A synthesis" patented technology

The invention discloses a paclitaxel lipid complex. The paclitaxel lipid complex consists of paclitaxel and lipid material. The weight proportion of the paclitaxel and the lipid material is 1 to 1 - 19, the preferential proportion is 1 to 2 - 10, and the more preferential proportion is 1 to 3 - 6. The lipid material is selected from natural lipid and synthetic lipid or the mixture thereof. The paclitaxel lipid complex can also contain antioxidation stabilizer. The invention also discloses a preparation method of the paclitaxel lipid complex and the application in the preparation of injection submicron emulsion and dry emulsion. The paclitaxel lipid complex has high solubility in oil, and the prepared submicron emulsion has the advantages of high drug loading quantity, high stability, high safety and low irritability.

The invention discloses an application of soluble dietary fibers in kelp in preparation of lipid-lowering and weight-losing medicines and functional foods. The soluble dietary fibers are extracted from the waste kelp residues, after feeding for 3 weeks, the weight of obese mice is remarkably reduced compared with that of a negative control group; after 6 weeks of experiment period, the lipid-lowering effect is obvious; the epididymis fat and the liver of a mouse are subjected to histopathological section, the soluble dietary fibers in the section dyed by HE can obviously reduce the size of thefat, and the fat lesion of the liver of the mouse is relieved. By detecting mRNA expression of related factors related to lipid metabolism in fat and liver and mRNA expression of common inflammatoryfactors in obesity, the soluble dietary fibers can down-regulate expression of lipid synthesis genes and pro-inflammatory factors and up-regulate expression of lipid metabolism genes. The soluble dietary fiber disclosed by the invention is high in safety and low in price, and has a remarkable effect in the aspects of reducing fat and losing weight of OB obese mice.

The invention discloses heterocyclic modulators of lipid synthesis for use against cancer and viral infections. According to the invention, also provided are heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and methods of treating conditions characterized by disregulation of a fatly acid synthase pathway by the administration of such compounds.

The invention discloses miRNA markers of lipid synthesis ability under whole grain diet, and belongs to the fields of biomedicine, food nutrition and health. The present invention intervenes the lipid metabolism of the body through the whole grain diet, and verifies the role of miR-27a-3p in the lipid metabolism through the analysis of the lipid metabolism of the body, the sequencing analysis of serum miRNAs, and the efficacy evaluation of miR-27a-3p in the lipid metabolism function. Biological roles during synthesis. miR‑27a‑3p can be used as a new serum miRNA biomarker for whole grain diet to regulate lipid metabolism in the body.

The invention discloses beta-isopropylmalate dehydrogenase and application of the beta-isopropylmalate dehydrogenase in lipid synthesis, and belongs to the technical fields of gene engineering and microbial engineering. An amino acid sequence of the beta-isopropylmalate dehydrogenase is shown in SEQ ID No. 1, and the beta-isopropylmalate dehydrogenase has a function of promoting microorganism to produce fatty acids. Recombinant mortierella alpina containing the beta-isopropylmalate dehydrogenase is subjected to shake cultivation for 7 d, so that the fatty acid content in the mortierella alpinacontaining the beta-isopropylmalate dehydrogenase can reach 46.4% of dry cell weight, and is 20.2% higher than that of mortierella alpina without the beta-isopropylmalate dehydrogenase. According tothe beta-isopropylmalate dehydrogenase, through gene engineering, the fatty acid production ability of the mortierella alpine and other oil producing microorganisms is further improved, and solid theoretical support for improving the fatty acid biosynthesis ability is provided.

The invention provides an application of a transcription factor KLF16 protein in the preparation of drugs for preventing and treating diseases related to abnormal lipid and glucose metabolism. The transcription factor KLF16 protein provided by the invention significantly reduces the blood sugar and blood lipid level in disease model animals by mediating and regulating the expression of gluconeogenesis-related genes, and has effects of inhibiting gluconeogenesis and inhibiting lipid synthesis and deposition, and thereby inhibits the progress of hyperglycemia and hyperlipidemia. Therefore, the transcription factor KLF16 protein has the potential of preventing and treating diseases caused by hyperglycemia and hyperlipidemia such as diabetes, diabetic complications, obesity, hyperinsulinemia,hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and arteriosclerosis, and a new target for the prevention and treatment of the above-mentioned diseases, especially type II diabetes and obesity is provided. The KLF16 protein has no toxic side effects, has good safety, can adapt to the industrial application of new drugs, and has good clinical application prospect.

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and / or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.

The invention relates to a corn oil product with the function of regulating lipid metabolism and a preparation method thereof. The sterol content in the corn oil product is 800-4800mg / 100g, the vitamin E content is 22-290mg / 100g, and the red value R is 0.6-3.0. While the corn oil product of the invention is rich in sterols and vitamin E, it also has a color red value R in a specific range, helps to reduce blood triglyceride and cholesterol, and has the energy efficiency of inhibiting lipid synthesis in the liver. The preparation method of the corn oil product of the invention is simple and scientific, and can simultaneously realize the improvement of sterol and vitamin E content and the control of color without using a decolorizing agent.

The invention belongs to the technical field of pharmaceutical preparations and particularly relates to application of theaflavin TF3 to preparation of a PK (plasma kallikrein) inhibitor and medicinesfor NAFLD (non-alcoholic fatty liver disease) treatment. By a direct inhibition effect of tea monomer theaflavin TF3 (theaflavin-3, 3'-gallate) on PK targets in NAFLD liver cells, TF3 is capable of remarkably inhibiting PK enzymatic activity and further remarkably activating AMPK signal routing after PK inhibition to reduce lipid synthesis protein expression and activate or stimulate lipidolysisprotein expression and is also capable of reducing accumulation of intracellular lipids through PK activity inhibition. Therefore, the theaflavin TF3 can be used as a newly discovered PK inhibitor with a certain regulation function in fat metabolism pathway, plays a key role in NAFLD improvement, has an effect of NAFLD treatment or alleviation and can be applied to medicines for NAFLD prevention,treatment or alleviation.

The invention relates to the application of nomilin in the preparation of medicines for improving liver damage caused by cholestasis and metabolic diseases, and belongs to the technical field of medicine preparation. The present invention provides the application of nomilin in the preparation of medicines for improving liver damage caused by cholestasis and metabolic diseases. Nomilin can significantly improve liver damage by improving bile acid metabolism, anti-inflammatory, anti-oxidative stress, and reducing lipid synthesis.

The present invention relates to glycopeptides of the following formula I: or a tautomer, stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, in particular a racemic mixture, and / or a physiologically acceptable salt and / or solvate thereof, where:-n represents an integer from 1 to 6,-m represents 0 or 1,-p represents 0 or 1,-R represents H, F, CH3, CH2F or CH2OH, and / or a pharmaceutically acceptable salt and / or solvate thereof. -R1, R2, and R3 independently of each other represent H, F, or OH,-R4 represents hydrogen, halogen, or OH,-R6 and R7 independently of each other represent hydrogen, (C1-C6) alkyl, aryl, or aryl-(C1-C6) alkyl, and-R8 represents H or CO-(C1-C20) alkyl, used for plumping and / or plumping and / or densifying and / or filling wrinkles and / or moisturizing and / or restoring lipids of skin or hair and / or stimulating hair growth and / or for treating skin dryness and / or atopic dermatitis and / or atopic eczema and / or scurf due to its ability to increase lipid synthesis diseases.

Phototropin is a blue light receptor, which mediates a variety of blue-light elicited physiological processes in plants and algae. In higher plants these processes include phototropism, chloroplast movement and stomatal opening. In the green alga Chlamydomonas reinhardtii, phototropin plays a vital role in progression of the sexual life cycle and in the control of the eye spot size and light sensitivity Phototropin is also involved in blue-light mediated changes in the synthesis of chlorophylls, carotenoids, chlorophyll binding proteins. We compared the transcriptome of phototropin knock out (PHOT KO) mutant and wild-type parent to analyze differences in gene expression in high light grown cultures (500 μmol photons m−2 s−1). Our results indicate the up-regulation of genes involved in photosynthetic electron transport chain, carbon fixation pathway, starch, lipid, and cell cycle control genes. With respect to photosynthetic electron transport genes, genes encoding proteins of the cytochrome b6f and ATP synthase complex were up regulated potentially facilitating proton-coupled electron transfer. In addition genes involved in limiting steps in the Calvin cycle Ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO), Sidoheptulose 1,7 bisphosphatase (SBPase), Glyceraldehyde-3-phosphate dehydrogenase (3PGDH) and that mediate cell-cycle control (CDK) were also up regulated along with starch synthase and fatty acid biosynthesis genes involved in starch and lipid synthesis. In addition, transmission electron micrographs show increased accumulation of starch granules in PHOT mutant compared to wild type, which is consistent with the higher expression of starch synthase genes. Collectively, the altered patterns of gene expression in the PHOT mutants were associated with a two-fold increase in growth and biomass accumulation compared to wild type when grown in environmental photobioreactors (Phenometrics) that simulate a pond environment. In conclusion, our studies suggest that phototropin may be a master gene regulator that suppresses rapid cell growth and promotes gametogenesis and sexual recombination in wild type strains.

Compounds that are modulators of fatty acid synthesis are provided. The compounds are useful in the treatment of disorders characterized by dysfunctional fatty acid synthase by modulating fatty acid synthase function and / or fatty acid synthase pathway. Methods are provided for treating such disorders, including viral infections, such as hepatitis C infection, cancer, and metabolic disorders.

The invention relates to health products with hypolipemic function and also relates to a preparation method for the health products and the usage thereof. The health products comprise active constituents of hongqu powder, hawthorn extract, ginkgo biloba leaf extract, obtuseleaf senna seed extract and radix salviae miltiorrhizae extract. The active constituents have very obvious synergistic effect, thus playing a positive role in hypolipemic in many aspects such as reducing endogenous lipid synthesis, promoting the transfer and excretion of lipid, regulating lipid metabolism and the like, having obvious hypolipemic effect; safety toxicity test proves that the active constituents are safe, innoxious and harmless.

The invention relates to a cell culture medium. The cell culture medium contains a basal culture medium, a serum substitute, linoleic acid, testosterone, vitamin A, L-ascorbic acid, polylysine, putrescine, and 2-mercaptoethanol. The cell culture medium of the invention can efficiently culture sebaceous gland cells in vitro, so that a cell proliferation rate, a survival rate after resuscitation, and an expression amount of lipid synthesis related proteins of different generations of the sebaceous gland cells are significantly increased, and thereby the assistance for extensively researching sebaceous gland physiological and endocrine functions, exploring pathogenesis of sebaceous gland related diseases, and developing drugs is provided.

The invention discloses a citrate transporter and its application in lipid synthesis, belonging to the technical fields of genetic engineering and microbial engineering. The citrate-ketoglutarate transporter of the present invention whose amino acid sequence is shown in SEQ ID No.1 has the function of promoting fatty acid production by microorganisms, and the recombinant Mortierella alpina containing the citrate-ketoglutarate transporter of the present invention will be After 7 days of culture on a shaking table, the fatty acid content of Mortierella alpina containing the citric acid-ketoglutarate transporter of the present invention can reach 36.1% of the dry cell weight, which is lower than that of the Mortierella alpina that does not contain the citric acid-ketoglutarate transporter of the present invention. The fatty acid content of Mortierella alpina increased by 30.4%. The present invention improves the lipid synthesis and accumulation capacity of oleaginous microorganisms such as Mortierella alpina at the genetic level by means of genetic engineering, and at the same time ensures the normal growth of oleaginous microorganisms, thereby providing technical support for more efficient industrial production of microbial oils .

The invention relates to a recombinant bacterium for coordinately expressing glucose-6-phosphate dehydrogenase (G6PD)2 and malic enzyme (ME)2 in mortierella alpine, and further relates to a constructing method of the strain and an application of the strain. According to the recombinant bacterium, the constructing method and the application, the high-arachidonic-acid-yield mortierella alpine gene recombinant strain is constructed with mortierella alpine uracil auxotroph as a material; the important effects of the G6PD2 and the ME2 in the fatty acid synthesis process and the fatty acid desaturation process are verified; due to coordinate and ectopic expression of the two genes, the effects of increasing the yield and the desaturation degree of fatty acid are effectively achieved at the same time, the proportion of ARA in the total fatty acid is remarkably increased, fermentation time is effectively shortened, and the recombinant bacterium is of great significance in lipid synthesis basic principle researching and product development of the oil-producing fungus in mortierella alpine ATCC 32222.